✦ LIBER ✦

The Interval to Biochemical Failure Is Prognostic for Metastasis, Prostate Cancer-Specific Mortality, and Overall Mortality After Salvage Radiation Therapy for Prostate Cancer

✍ Scribed by Johnson, Skyler; Jackson, William; Li, Darren; Song, Yeohan; Foster, Corey; Foster, Ben; Zhou, Jessica; Vainshtein, Jeffrey; Feng, Felix; Hamstra, Daniel

Book ID: 123279439
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 405 KB
Volume: 86
Category: Article
ISSN: 0360-3016
DOI: 10.1016/j.ijrobp.2013.02.016

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The Interval to Biochemical Failure Is P

The Interval to Biochemical Failure Is Prognostic for Metastasis, Prostate Cancer-Specific, and Overall Mortality Following Salvage Radiation Therapy for Prostate Cancer

✍ Johnson, S.; Jackson, W.C.; Foster, C.; Li, D.; Palapattu, G.S.; Sandler, H.M.; 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 49 KB

Larger Maximum Tumor Diameter at Radical

Larger Maximum Tumor Diameter at Radical Prostatectomy Is Associated With Increased Biochemical Failure, Metastasis, and Death From Prostate Cancer After Salvage Radiation for Prostate Cancer

✍ Johnson, Skyler B.; Hamstra, Daniel A.; Jackson, William C.; Zhou, Jessica; Fost 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 375 KB

Time to Prostate-Specific Antigen Nadir

Time to Prostate-Specific Antigen Nadir After Androgen Suppression Therapy for Postoperative or Postradiation PSA Failure and Risk of Prostate Cancer-Specific Mortality

✍ Christine S. Chung; Ming-Hui Chen; Jennifer Cullen; David McLeod; Peter Carroll; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 291 KB

Time to Prostate-Specific Antigen Nadir

Time to Prostate-Specific Antigen Nadir After Androgen Suppression Therapy for Postoperative or Postradiation PSA Failure and Risk of Prostate Cancer-Specific Mortality

✍ Andriole, G.L. 📂 Article 📅 2008 🏛 Elsevier Science ⚖ 74 KB

Time to an undetectable prostate-specifi

Time to an undetectable prostate-specific antigen (PSA) after androgen suppression therapy for postoperative or postradiation PSA recurrence and prostate cancer-specific mortality

✍ Anthony V. D'Amico; David G. McLeod; Peter R. Carroll; Jennifer Cullen; Ming-Hui 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 172 KB

## Abstract ## BACKGROUND For men receiving androgen‐suppression therapy (AST) for a rising postoperative or postradiation prostate‐specific antigen (PSA) recurrence, whether the time to an undetectable (u) PSA was significantly associated with prostate cancer‐specific mortality (PCSM) was evaluat

Time to biochemical failure and prostate

Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial

✍ James W Denham; Allison Steigler; Chantelle Wilcox; David S Lamb; David Joseph; 📂 Article 📅 2008 🏛 The Lancet 🌐 English ⚖ 282 KB